Orthofix Medical Inc. has chosen Michael Finegan to chair its Board of Directors.
 
Finegan joined Orthofix’s board in December 2023. He is CEO at Acera Surgical, a bioscience company developing and commercializing engineered synthetic materials for soft tissue repair and regenerative medicine. Before leading Acera, Finegan spent 14 years at Orthofix, where he served in roles of increasing responsibility, including seven years as chief strategy officer.
 
“I have a long history with Orthofix, and it is an honor to be selected to lead the Board of Directors,” Finegan said. “The company has undergone a transformation and I believe is well-positioned to deliver profitable growth and significant, sustainable shareholder value as we fulfill our mission of providing life-changing solutions for patients.”

Prior to his Orthofix tenure, Finegan served more than 16 years in variety roles at Boston Scientific Corp. Finegan earned a bachelor of arts degree in economics from Wake Forest University.
 
“We are grateful to former Chair Cathy Burzik for her outstanding leadership, and I would like to thank her for all she has done for Orthofix and wish her the best as she continues to make a difference in the healthcare industry,” Orthofix President/CEO Massimo Calafiore stated. “We are also excited to welcome Michael as our new chair. His years of experience in the industry and specifically with Orthofix, will provide the board with an important dimension and a tremendously valuable perspective to take us into our next chapter of growth.”
 
Orthofix is a global spine and orthopedics company with a portfolio of biologics, spinal hardware, bone growth therapies, specialized orthopedic solutions, and a surgical navigation system. Its products are distributed in more than 60 countries worldwide. The company is headquartered in Lewisville, Texas, where it conducts general business, product development, medical education and manufacturing, and has primary offices in Carlsbad, Calif., with a focus on spine and biologics product innovation and surgeon education, and Verona, Italy, with an emphasis on product innovation, production, and medical education for orthopedics. The combined company’s global R&D, commercial and manufacturing footprint also includes facilities and offices in Irvine, Calif.; Toronto, Canada; Sunnyvale, Calif.; Maidenhead, U.K.; Munich, Germany; Paris; and São Paulo, Brazil.